Somatic Pain Associated with Initiation of Interferon-alpha (IFN-α) Plus Ribavirin (RBV) Therapy in Chronic HCV Patients: A Prospective Study

Overview

Journal Brain Behav Immun Health

Date 2021 Sep 30

PMID 34589826

Citations 5

Authors

Chih Ying Lin

Ta-Wei Guu

Hsueh-Chou Lai

Cheng-Yuan Peng

Jill Yi-Ju Chiang

Hui-Ting Chen

Tsai-Chung Li

Shing-Yu Yang

Kuan-Pin Su

Jane Pei-Chen Chang

Affiliations

Soon will be listed here.

Abstract

Objective: This study is aimed to investigate the association between interferon-alpha (IFN-α) plus ribavirin (RBV) treatment and emergence of somatic pain symptoms in patients with hepatitis C virus (HCV) over a 24-week treatment.

Method: In this prospective cohort study, 297 patients with HCV were evaluated at baseline and 2nd, 4th, 8th, 12th, 16th, 20th, and 24th week with structured Mini-International Neuropsychiatric Interview for Major Depressive Disorder (MDD) diagnosis and the Neurotoxicity Rating Scale (NRS) for somatic symptoms.

Results: Eighty-seven out of the 297 patients (29%) developed IFN-α induced depression and had significantly higher somatic pain symptoms as early as the 2nd week and at all the assessment time points ( < .001). Most depressed patients perceived greatest somatic pain at the 8th week of treatment. Moreover, NRS somatic pain scores after initial therapy strongly correlated with NRS somatic pain scores at all other assessment time points ( < .001).

Conclusion: IFN-α therapy induce significant somatic pain as early as the 2nd week of treatment in HCV patients who later developed MDD. Thus, initial NRS somatic pain score after initiation of IFN-α treatment may serve as a reference for the susceptibility of the individual to IFN-α induced depression.

Citing Articles

Exploring blood transcriptomic signatures in patients with herpes zoster and postherpetic neuralgia.

Wang C, Zhang K, Bao Y, Liu Y, Zhou Y, Ji Y Front Cell Infect Microbiol. 2024; 14:1425393.

PMID: 39211798 PMC: 11358128. DOI: 10.3389/fcimb.2024.1425393.

Vinorelbine causes a neuropathic pain-like state in mice via STING and MNK1 signaling associated with type I interferon induction.

Franco-Enzastiga U, Natarajan K, David E, Patel K, Ravirala A, Price T iScience. 2024; 27(2):108808.

PMID: 38303713 PMC: 10831286. DOI: 10.1016/j.isci.2024.108808.

Microglial STING activation alleviates nerve injury-induced neuropathic pain in male but not female mice.

Prudente A, Lee S, Roh J, Luckemeyer D, Cohen C, Pertin M Brain Behav Immun. 2024; 117:51-65.

PMID: 38190983 PMC: 11034751. DOI: 10.1016/j.bbi.2024.01.003.

Mechanism and effects of STING-IFN-I pathway on nociception: A narrative review.

Yang J, Ding H, Shuai B, Zhang Y Front Mol Neurosci. 2023; 15:1081288.

PMID: 36683857 PMC: 9846240. DOI: 10.3389/fnmol.2022.1081288.

What role of the cGAS-STING pathway plays in chronic pain?.

Wu J, Li X, Zhang X, Wang W, You X Front Mol Neurosci. 2022; 15:963206.

PMID: 35979145 PMC: 9376357. DOI: 10.3389/fnmol.2022.963206.

References

Raison C, Borisov A, Broadwell S, Capuron L, Woolwine B, Jacobson I . Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry. 2005; 66(1):41-8. PMC: 1615913. DOI: 10.4088/jcp.v66n0106. View

Raison C, Demetrashvili M, Capuron L, Miller A . Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005; 19(2):105-23. PMC: 1255968. DOI: 10.2165/00023210-200519020-00002. View

Horikawa N, Yamazaki T, Izumi N, Uchihara M . Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry. 2003; 25(1):34-8. DOI: 10.1016/s0163-8343(02)00239-6. View

Kroenke K . Patients presenting with somatic complaints: epidemiology, psychiatric comorbidity and management. Int J Methods Psychiatr Res. 2003; 12(1):34-43. PMC: 6878426. DOI: 10.1002/mpr.140. View

Kapfhammer H . Somatic symptoms in depression. Dialogues Clin Neurosci. 2006; 8(2):227-39. PMC: 3181769. View

Valentine A, Meyers C, Kling M, Richelson E, Hauser P . Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol. 1998; 25(1 Suppl 1):39-47. View

Loftis J, Patterson A, Wilhelm C, McNett H, Morasco B, Huckans M . Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study. J Psychosom Res. 2013; 74(1):57-63. PMC: 4408920. DOI: 10.1016/j.jpsychores.2012.10.012. View

Bekhuis E, Boschloo L, Rosmalen J, Schoevers R . Differential associations of specific depressive and anxiety disorders with somatic symptoms. J Psychosom Res. 2014; 78(2):116-22. DOI: 10.1016/j.jpsychores.2014.11.007. View

Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E . The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1999; 59 Suppl 20:22-33;quiz 34-57. View

10.

Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S . Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol. 2012; 57(6):1379-90. DOI: 10.1016/j.jhep.2012.07.037. View

11.

Fontana R, Hussain K, Schwartz S, Moyer C, Su G, Lok A . Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol. 2002; 36(3):401-7. DOI: 10.1016/s0168-8278(01)00280-x. View

12.

Feld J . The beginning of the end: what is the future of interferon therapy for chronic hepatitis C?. Antiviral Res. 2014; 105:32-8. DOI: 10.1016/j.antiviral.2014.02.005. View

13.

Tamayo J, Roman K, Fumero J, Rivas M . The level of recognition of physical symptoms in patients with a major depression episode in the outpatient psychiatric practice in Puerto Rico: an observational study. BMC Psychiatry. 2005; 5:28. PMC: 1183226. DOI: 10.1186/1471-244X-5-28. View

14.

Fishbain D . The association of chronic pain and suicide. Semin Clin Neuropsychiatry. 1999; 4(3):221-7. DOI: 10.153/SCNP00400221. View

15.

Huckans M, Fuller B, Wheaton V, Jaehnert S, Ellis C, Kolessar M . A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C. J Psychosom Res. 2014; 78(2):184-92. PMC: 4435678. DOI: 10.1016/j.jpsychores.2014.07.020. View

16.

Udina M, Hidalgo D, Navines R, Forns X, Sola R, Farre M . Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry. 2014; 75(10):e1113-21. DOI: 10.4088/JCP.13r08800. View

17.

Khan A, Khan A, Harezlak J, Tu W, Kroenke K . Somatic symptoms in primary care: etiology and outcome. Psychosomatics. 2003; 44(6):471-8. DOI: 10.1176/appi.psy.44.6.471. View

18.

Diez-Quevedo C, Masnou H, Planas R, Castellvi P, Gimenez D, Morillas R . Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010; 72(4):522-8. DOI: 10.4088/JCP.09m05282blu. View

19.

Kirkwood J, Strawderman M, Ernstoff M, Smith T, Borden E, Blum R . Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996; 14(1):7-17. DOI: 10.1200/JCO.1996.14.1.7. View

20.

Li M, Kouzmina E, McCusker M, Rodin D, Boutros P, Paige C . Pro- and anti-inflammatory cytokine associations with major depression in cancer patients. Psychooncology. 2016; 26(12):2149-2156. DOI: 10.1002/pon.4316. View